YYYan Yan

Yan Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yan Yan has a total of 153 co-authors. Here are the top co-authors by number of shared publications:

  • Shaoping Nie

    Capital Medical University

    9 shared publications
  • Wei Gong

    Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; National Clinical Research Center of Cardiovascular Diseases, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China

    8 shared publications
  • Xiao Wang

    Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    6 shared publications
  • Gilles Montalescot

    Sorbonne Université, ACTION Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France

    4 shared publications
  • Hui Ai

    Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China

    4 shared publications
  • Changsheng Ma

    Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University

    3 shared publications

Latest Publications

  • Identification of Secreted Modular Calcium-Binding Protein 1 as a Novel Endogenous Protective Molecule Against Acute Myocardial Infarction–Induced Cardiac Rupture

    by Wei Gong, Siyi Li, Zekun Zhang, Yan Yan, Hui Ai, Yu Li, Theodore A. Christopher, Bernard Lopez, Xinliang (Xin) Ma, Shaoping Nie

    BACKGROUND: Cardiac rupture is a catastrophic complication of acute myocardial infarction (AMI), with poorly understood molecular mechanisms and no available therapeutic interventions. METHODS: Plasma samples were obtained from patients with AMI and animal models, while left ventricular tissue was collected from AMI mice. An unbiased proteomics analysis identified proteins significantly altered in patients with AMI with cardiac rupture. To explore causal relationships and underlying mechanisms, we used loss- and gain-of-function animal models. RESULTS: Proteomics analysis revealed that 9 proteins were significantly upregulated and 24 proteins were significantly downregulated in patients with AMI with cardiac rupture compared with those without. Among these, SMOC-1 (secreted modular calcium-binding protein 1) was the most significantly upregulated protein. Validation in extended patient cohorts and animal models confirmed these findings. A time-course study revealed that SMOC-1 expression was transiently elevated, peaking 1 day after AMI and returning to baseline within a week. Immunological and cell-specific analyses identified cardiomyocytes as the predominant source of SMOC-1 in response to AMI. Surprisingly, cardiomyocyte-specific SMOC-1 knockout doubled the incidence of post-AMI cardiac rupture and reduced survival, while adeno-associated virus serotype 9–mediated SMOC-1 overexpression significantly decreased cardiac rupture rates. Mechanistic studies revealed that cardiomyocyte-derived SMOC-1 supports fibrosis by activating fibroblasts, enhancing collagen synthesis, and promoting collagen maturation, all of which are critical for the formation of reparative scars. SMOC-1 was shown to bind TGF-βR1 (transforming growth factor β receptor 1) in fibroblasts, recruiting EPRS (glutamyl-prolyl-tRNA synthetase) to form a signaling complex that activates the Smad pathway. Inhibiting EPRS abolished the profibrotic effects of SMOC-1. CONCLUSIONS: Our study provides the first evidence that the transient upregulation and secretion of cardiomyocyte-derived SMOC-1 constitute an intrinsic profibrotic and antirupture response to severe ischemic injury. However, this natural protective mechanism is insufficient to fully prevent cardiac rupture, highlighting the potential of enhancing the SMOC-1 pathway as a promising therapeutic strategy to mitigate cardiac rupture and reduce AMI-associated mortality.


  • Open Access

    Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention

    by Yan Yan, Xiao Wang, Zeyuan Fan, Jincheng Guo, Guozhong Wang, Delu Yin, Zhifang Wang, Fuchun Zhang, Changming Tian, Wei Gong, et al.


  • Open Access

    Association between time-weighted average glucose concentration or glucose variability and acute kidney injury among coronary artery disease patients with prediabetes

    by Jiaxin Ren, Ge Wang, Yizhe Zhou, Wei Gong, Hongjia Zhang, Yan Yan

    To validate the effectiveness of intensive glycemic control in preventing acute kidney injury (AKI) among patients with coronary artery disease (CAD) and prediabetes. This investigation employed data from the Prospective Registry of the Current Status of Care for Patients with CAD database. Glycemic control was evaluated using the time-weighted average glucose (TWAG) and the glucose coefficient of variation (CV) for each participant. The primary outcome was AKI occurrence. A total of 2,454 CAD patients with prediabetes were included between January 2022 and June 2023. The mean age was 62.6 ± 10.3 years, with 27.1% female. In univariate analysis, each 1 mmol/L increase in TWAG was associated with a 1.51-fold (95% confidence interval (CI): 1.36-1.68) higher incidence of AKI. After stepwise adjustment for covariates, the odds ratio (OR) remained significant at 1.50 (95% CI: 1.35-1.67). Similarly, glucose CV showed a positive correlation with AKI risk; a 0.1-unit increase in CV was linked to approximately a 44% higher risk. When both TWAG and CV were included simultaneously in the model, each maintained an independent positive association with AKI. Restricted cubic spline analyses revealed a dose-dependent increase in AKI risk with rising TWAG and CV. Subgroup analyses confirmed the positive relationship between TWAG, glucose variability, and AKI risk. Our study reveals an association between TWAG or CV of glucose and AKI in individuals with both CAD and prediabetes. These findings highlight the potential value of continuous glucose monitoring and managing glycemic variability to reduce AKI risk in this population.

  • Open Access

    In‐Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC‐ACS Project

    by Wei Gong, Yan Yan, Jing Liu, Xiao Wang, Wen Zheng, Bin Que, Hui Ai, Sidney C. Smith, Gregg C. Fonarow, Louise Morgan, et al.

    Background: Patients with acute coronary syndrome without standard modifiable cardiovascular risk factors (SMuRFs; hypertension, smoking, dyslipidemia, diabetes) have not been well studied, with little known about their characteristics, quality of care, or outcomes. We sought to systematically analyze patients with ACS without SMuRFs, especially to evaluate the effectiveness of guideline‐directed medical therapy for these patients. Methods and Results: In the CCC‐ACS (Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome) project (2014–2019), we examined the presence and absence of SMuRFs and features among 89 462 patients with initial acute coronary syndrome. The main outcome was in‐hospital all‐cause mortality. Among eligible patients, 11.0% had none of the SMuRFs (SMuRF‐less). SMuRF‐less patients had higher in‐hospital mortality (unadjusted hazard ratio [HR], 1.49 [95% CI, 1.19–1.87]). After adjustment for clinical characteristics and treatments, the associations between SMuRF status and in‐hospital mortality persisted (adjusted HR, 1.35 [95% CI, 1.07–1.70]). Guideline‐directed optimal medical therapy (receiving angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, β‐blockers, and statins) was not associated with lower mortality (adjusted HR, 0.98 [95% CI, 0.58–1.67]) in SMuRF‐less patients, unlike the association in patients with SMuRFs (adjusted HR, 0.80 [95% CI, 0.66–0.98]). Sensitivity analyses were consistent with these results. Conclusions: SMuRF‐less patients were associated with an increased risk of in‐hospital mortality. Guideline‐directed medical therapy was less effective in SMuRF‐less patients than in patients with SMuRFs. Dedicated studies are needed to confirm the optimal therapy for SMuRF‐less patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02306616.


  • Open Access

    Incremental value of high-risk CMR attributes to predict adverse remodeling after ST-segment elevation myocardial infarction across LVEF categories

    by Qian Guo, Xiao Wang, Ruifeng Guo, Yingying Guo, Yan Yan, Wei Gong, Wen Zheng, Hui Wang, Lei Xu, Bin Que, et al.


  • Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial

    by Yan Yan, Jincheng Guo, Xiao Wang, Guozhong Wang, Zeyuan Fan, Delu Yin, Zhifang Wang, Fuchun Zhang, Changming Tian, Wei Gong, et al.

    BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment–elevation myocardial infarction, although no conclusive data support this practice. METHODS: The RIGHT trial (Comparison of Anticoagulation Prolongation vs no Anticoagulation in STEMI Patients After Primary PCI) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at 53 centers in China. Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Before trial initiation, each center selected 1 of 3 PPA regimens (40 mg of enoxaparin once daily subcutaneously; 10 U·kg·h of unfractionated heparin intravenously, adjusted to maintain activated clotting time between 150 and 220 seconds; or 0.2 mg·kg·h of bivalirudin intravenously). The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. The key secondary objective was to evaluate the effect of each specific anticoagulation regimen (enoxaparin, unfractionated heparin, or bivalirudin) on the primary efficacy end point. The primary safety end point was Bleeding Academic Research Consortium 3 to 5 bleeding at 30 days. RESULTS: Between January 10, 2019, and September 18, 2021, a total of 2989 patients were randomized. The primary efficacy end point occurred in 37 patients (2.5%) in both the PPA and placebo groups (hazard ratio, 1.00 [95% CI, 0.63 to 1.57]). The incidence of Bleeding Academic Research Consortium 3 to 5 bleeding did not differ between the PPA and placebo groups (8 [0.5%] vs 11 [0.7%] patients; hazard ratio, 0.74 [95% CI, 0.30 to 1.83]). CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03664180.


  • Open Access

    Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia

    by Siyi Li, Qingjie Xin, Yan Yan, Xiao Wang, Hui Ai, Bin Que, Wei Gong, Shaoping Nie

    The role of phosphodiesterase 5 (Pde5) in obstructive sleep apnea–induced damage remains unclear. Our study aimed to investigate the role of Pde5 in the chronic intermittent hypoxia (CIH) model. C57BL/6J wild-type (WT) mice (n = 48) and Pde5 knockout (Pde5−/−) mice (n = 24) were randomly assigned to CIH group and room air group. After 6 weeks, some WT mice (n = 24) in CIH group were given sildenafil or saline gavage for another 4 weeks. Blood pressure was regularly measured during the experiment. Echocardiography was used to estimate cardiac function. We collected organs from each group of mice and measured their physical indicators. Histochemical staining was used to explore the size of cardiomyocyte and fibrosis area of various organs. Cyclic guanosine monophosphate and malondialdehyde concentrations in serum were measured by ELISA assay. Compared with the RA-treated group, the 6-week CIH resulted in a significant increase in blood pressure, altered heart structure, and reduced serum cyclic guanosine monophosphate in WT mice. Pde5−/− mice and sildenafil intragastric administration significantly reduced systolic blood pressure in CIH condition and attenuated the damage of target organs. In CIH model, we found that the cardiomyocyte size and fibrosis area of heart and kidney significantly reduced in Pde5−/− groups. Besides, endogenous and exogenous inhibition of Pde5 reduced malondialdehyde level and inflammatory and oxidative stress markers expression in CIH condition. In this study, we found that Pde5 inhibition could reduce blood pressure and alleviate target organ damage in the CIH model, which may be mediated through the oxidative stress pathway.


  • Open Access

    Effect of complete revascularization in acute coronary syndrome after 75 years old: insights from the BleeMACS registry

    by Ge Wang, Xiu-Huan Chen, Si-Yi Li, Ze-Kun Zhang, Wei Gong, Yan Yan, Shao-Ping Nie, José P. Henriques

    BACKGROUND The prognostic benefit of complete revascularization in elderly patients (aged over 75 years) with multi-vessel disease and acute coronary syndrome (ACS) is currently unclear. This study aimed to determine the long-term prognostic impact of complete revascularization in this population. METHODS We conducted this study using data obtained from the BleeMACS (Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome) registry, which was carried out from 2003 to 2014. The objective was to categorize older patients diagnosed with ACS into two groups: those who underwent complete revascularization and those who did not. Propensity score matching and the Kaplan-Meier analysis were employed to examine differences in one-year clinical outcomes. The primary endpoint was major adverse cardiovascular event (MACE), which encompassed a combination of all-cause mortality and myocardial infarction. RESULTS Out of 1263 patients evaluated, 445 patients (35.2%) received complete revascularization. Patients who underwent complete revascularization had a higher prevalence of hypertension and prior percutaneous coronary intervention compared to those who did not. During the one-year follow-up period, complete revascularization was associated with a significantly decreased risk of MACE [13.7% vs. 20.5%, hazard ratio (HR) = 0.63, 95% CI: 0.45–0.88, P = 0.007] and a lower risk of myocardial infarction (5.9% vs. 9.9%, HR = 0.55, 95% CI: 0.33–0.92, P = 0.02). However, it was not linked to a lower risk of all-cause death (9.5% vs. 13.5%, HR = 0.68, 95% CI: 0.45–1.02, P = 0.06). Similar results were observed in the subgroup analysis. CONCLUSIONS Long-term clinical improvements were observed in ACS patients aged over 75 years with multi-vessel disease who achieved complete revascularization. Therefore, adhering to guidelines for complete revascularization should be recommended for elderly patients.